TheraSolve NV announced today the closure of its first financing round co-led by Thuja Capital and LRM. With the investment TheraSolve will be able to develop and initiate commercialization of its innovative MemoPatch device to enhance treatment adherence. TheraSolve NV was founded in 2009 by a team of engineers and healthcare experts who developed a smart digital touch patch technology. The management team consists of Wim De Geest, MSc (CEO), Jan De Geest, MSc (CTO) and Ivo Abraham, PhD (CSO). In connection with this financing round TheraSolve will relocate its premises to the life sciences incubator BioVille at the Hasselt University campus.
